GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Annual Study for Fluarix Registration
- Conditions
- Influenza
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT00306943
- Locations
- 🇩🇪
GSK Investigational Site, Dresden, Sachsen, Germany
Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule
- Conditions
- Infections, Streptococcal
- Interventions
- Biological: GSK Biologicals' 10-valent pneumococcal conjugate vaccine.Biological: Infanrix hexa.Biological: Infanrix-IPV/Hib.
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 351
- Registration Number
- NCT00307034
- Locations
- 🇸🇪
GSK Investigational Site, Örebro, Sweden
Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
- Conditions
- Influenza VaccinesInfluenza
- Interventions
- Biological: SB218352_4Biological: SB218352_2Biological: SB218352_8ALBiological: SB218352_2ALBiological: SB218352_4ALBiological: SB218352_15Biological: SB218352_8
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 385
- Registration Number
- NCT00306995
- Locations
- 🇩🇪
GSK Investigational Site, Elmshorn, Schleswig-Holstein, Germany
Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children
- Conditions
- Malaria
- Interventions
- Biological: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 180
- Registration Number
- NCT00307021
- Locations
- 🇬🇦
GSK Investigational Site, Lambaréné, Gabon
Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™
- Conditions
- Influenza
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1524
- Registration Number
- NCT00306982
- Locations
- 🇧🇷
GSK Investigational Site, São Paulo, Brazil
Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 556
- Registration Number
- NCT00306644
- Locations
- 🇸🇪
GSK Investigational Site, Malmö, Sweden
Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 388
- Registration Number
- NCT00306696
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
- Conditions
- Herpes Labialis
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00306293
- Locations
- 🇺🇸
GSK Investigational Site, Memphis, Tennessee, United States
A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
- Conditions
- Infections, Papillomavirus
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00306241
- Locations
- 🇭🇰
GSK Investigational Site, Hong Kong, Hong Kong
Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients
- Conditions
- Schizophrenia
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 275
- Registration Number
- NCT00300963
- Locations
- 🇺🇸
GSK Investigational Site, Richmond, Virginia, United States